ArQule Pleads Tivantinib’s Promise In Liver Cancer After Lung Cancer Blow-up
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After a progression-free survival benefit failed to translate into overall survival in a Phase III NSCLC study of ArQule/Daiichi Sankyo’s c-Met inhibitor tivantinib, ArQule is shifting focus to an imminent, targeted second-line Phase III study in high-Met expressing hepatocellular cancer.